Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance

被引：0
|
作者：
Makoto Tahara
Naomi Kiyota
Ken-ichi Nibu
Ayumi Akamatsu
Tomohiro Hoshino
Ryuichi Hayashi
机构：
[1] National Cancer Center Hospital East,Department of Head and Neck Medical Oncology
[2] Kobe University Hospital,Department of Medical Oncology and Hematology
[3] Kobe University Hospital,Cancer Center
[4] Kobe University School of Medicine,Department of Otolaryngology
[5] Ono Pharmaceutical Co.,Head and Neck Surgery
[6] Ltd.,Post Marketing Surveillance Pharmacovigilance Department
[7] Ono Pharmaceutical Co.,Safety Management Pharmacovigilance Department
[8] Ltd.,Department of Head and Neck Surgery
[9] National Cancer Center Hospital East,undefined
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Nivolumab; Head and neck cancer; Post-marketing surveillance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1619 / 1627
页数：8
相关论文
共 50 条
  • [1] Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
    Tahara, Makoto
    Kiyota, Naomi
    Nibu, Ken-ichi
    Akamatsu, Ayumi
    Hoshino, Tomohiro
    Hayashi, Ryuichi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (09) : 1619 - 1627
  • [2] Post-marketing survey of safety and efficacy of nivolumab for recurrent or metastatic head and neck cancer in Japan
    Kiyota, Naomi
    Tahara, Makoto
    Nibu, Ken-Ichi
    Hoshino, Tomohiro
    Iida, Osamu
    Hayashi, Ryuichi
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [3] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Hirotsugu Uemura
    Yoshihiko Tomita
    Norio Nonomura
    Kenji Yoshizaki
    Takafumi Nakao
    Nobuo Shinohara
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1061 - 1067
  • [4] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Nonomura, Norio
    Yoshizaki, Kenji
    Nakao, Takafumi
    Shinohara, Nobuo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (06) : 1061 - 1067
  • [5] Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan
    Takayama, Koichi
    Kojima, Ai
    Honda, Chikara
    Nakayama, Masahiro
    Kanemata, Satomi
    Endo, Toshimitsu
    Muro, Kei
    [J]. CANCER MEDICINE, 2024, 13 (09):
  • [6] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [7] The real-world use of istradefylline for Parkinsons disease: Post-marketing surveillance of safety and effectiveness in Japan
    Takahashi, Makio
    Itou, Satoru
    Horiguchi, Shuji
    Tsuji, Yukie
    [J]. NEUROLOGY, 2022, 98 (18)
  • [8] Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan
    Kawasaki, Akira
    Hatake, Kiyohiko
    Matsumura, Itaru
    Izutsu, Koji
    Hoshino, Tomohiro
    Akamatsu, Ayumi
    Kakuuchi, Akito
    Tobinai, Kensei
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 667 - 676
  • [9] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
    Maruyama, Dai
    Omi, Ai
    Nomura, Fumi
    Touma, Tokiko
    Noguchi, Yukiko
    Takebe, Kyoko
    Izutsu, Koji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (02) : 146 - 155
  • [10] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
    Dai Maruyama
    Ai Omi
    Fumi Nomura
    Tokiko Touma
    Yukiko Noguchi
    Kyoko Takebe
    Koji Izutsu
    [J]. International Journal of Hematology, 2024, 119 : 146 - 155
12345